Web resources for patients with prostate cancer: A starting point

2002 ◽  
Vol 20 (1) ◽  
pp. 32-38 ◽  
Author(s):  
Emily R. Lipp
Keyword(s):  
Prostate Cancer ◽  
Web Resources ◽  
Starting Point

scholarly journals Malignant websites? Analyzing the quality of prostate cancer education web resources

2018 ◽  
Vol 12 (10) ◽  
Author(s):  
Kevin Kobes ◽  
Ilene B. Harris ◽  
Glenn Regehr ◽  
Ara Tekian ◽  
Paris-Ann Ingledew
Keyword(s):  
Prostate Cancer ◽  
Grade Level ◽  
Cancer Education ◽  
School Level ◽  
Cancer Information ◽  
High School Level ◽  
Web Resources ◽  
Inaccurate Information ◽  
University Level

Introduction: Prostate cancer patients are using more web resources to inform themselves about their cancer. However, patients may receive out-of-date or inaccurate information due to lack of regulation. The current study looks to systematically analyze the quality of websites accessed by patients with prostate cancer.Methods: The term “prostate cancer” was searched in Google and the metasearch engines, Yippy and Dogpile, and the top 100 hits related to patient information were compiled from over 32 million hits. A standardized tool was used to examine 100 sites with respect to attribution, currency, usability, and content.Results: Of the top 100 websites relating to prostate cancer information, only 27% identified an author, of which 16% had their credentials displayed. The majority of websites disclosed ownership (97%). Over half of the websites did not include the date of the last update and of those that did, only 66% were current within two years. According to the Flesch Kincaid grade level tool for readability, the majority (87%) of sites were found to be at a high school level, while 6% were at university level. Finally, content varied among websites; 90% of sites provided information on detection and workup and treatments, but only 14% of sites included information on prognosis.Conclusions: The reliability of websites presenting prostate cancer information is questionable. There were noted deficiencies in attribution, currency, and readability. While information on detection and treatment is well-covered, information related to prognosis is lacking.

Using the Communication AssessmenT Checklist in Health to Assess the Communication Quality of Web Based Resources for Prostate Cancer

2017 ◽  
pp. 24-45
Author(s):  
Juliana Genova ◽  
Curtis A. Olson ◽  
Jackie Bender
Keyword(s):  
Prostate Cancer ◽  
Communication Quality ◽  
Prostate Cancer Treatment ◽  
Web Based ◽  
Web Resources ◽  
Strategic Intent ◽  
Communication Assessment ◽  
Treatment Information ◽  
Scientific Value

Introduction: The communication quality of web resources for patients is unknown. The purpose of this study was to assess prostate cancer websites using the Communication AssessmenT Checklist in Health (CATCH). Methods: CATCH is a theory-based tool consisting of 50 elements nested in 12 concepts. Two raters independently applied it to 35 HON certified websites containing information on prostate cancer treatment. Results: Websites contained a mean 24.1 (SD= 3.6) CATCH items. The concepts Language, Readability, Layout, Typography and Appearance were present in over 80% of sites. Content, Risk Communication, Usefulness, and Scientific Value were present in 50% or less. Discussion: The prostate cancer websites evaluated in this study did not present treatment information in a useful, informative or credible way for patients. The communication quality of these resources could be improved with a clear strategic intent focused on decision-making, using CATCH as a guiding framework.

Communication AssessmenT Checklist in Health

2017 ◽  
pp. 715-738
Author(s):  
Juliana Genova ◽  
Jackie Bender
Keyword(s):  
Prostate Cancer ◽  
Health Information ◽  
Communication Quality ◽  
Web Resources ◽  
Strategic Intent ◽  
Communication Assessment ◽  
Treatment Information ◽  
Patient Health ◽  
Scientific Value

There is no comprehensive and standardized tool for evaluating the communication quality of web resources for patients. The purpose of this study was to assess prostate cancer websites using the Communication AssessmenT Checklist in Health (CATCH) and to compare the results with those of the Consumer and Patient Health Information Section of the MLA (CAPHIS). CATCH is a theory-based tool consisting of 50 elements nested in 12 concepts. Two raters independently applied it to 35 HON certified websites containing information on prostate cancer treatment. The CATCH summary scores for these websites were then compared to the 2015 list of credible health websites published by CAPHIS. Websites contained a mean 24.1 (SD= 3.6) CATCH items. The concepts Language, Readability, Layout, Typography and Appearance were present in over 80% of sites. Content, Risk Communication, Usefulness, and Scientific Value were present in 50% or less. CATCH provided an overall score of the selected sites that was consistent with CAPHIS ratings. The prostate cancer websites evaluated in this study did not present treatment information in a useful, informative or credible way for patients. The communication quality of these resources could be improved with a clear strategic intent focused on decision-making, using CATCH as a guiding framework. CATCH is a tool that can be used independently or with other health resource evaluation tools to select the most trustworthy web resources for health information.

Using the Communication AssessmenT Checklist in Health to Assess the Communication Quality of Web Based Resources for Prostate Cancer

2017 ◽  
pp. 163-191
Author(s):  
Juliana Genova ◽  
Curtis A. Olson ◽  
Jackie Bender
Keyword(s):  
Prostate Cancer ◽  
Communication Quality ◽  
Prostate Cancer Treatment ◽  
Web Based ◽  
Web Resources ◽  
Strategic Intent ◽  
Communication Assessment ◽  
Treatment Information ◽  
Scientific Value

Introduction: The communication quality of web resources for patients is unknown. The purpose of this study was to assess prostate cancer websites using the Communication AssessmenT Checklist in Health (CATCH). Methods: CATCH is a theory-based tool consisting of 50 elements nested in 12 concepts. Two raters independently applied it to 35 HON certified websites containing information on prostate cancer treatment. Results: Websites contained a mean 24.1 (SD= 3.6) CATCH items. The concepts Language, Readability, Layout, Typography and Appearance were present in over 80% of sites. Content, Risk Communication, Usefulness, and Scientific Value were present in 50% or less. Discussion: The prostate cancer websites evaluated in this study did not present treatment information in a useful, informative or credible way for patients. The communication quality of these resources could be improved with a clear strategic intent focused on decision-making, using CATCH as a guiding framework.

Cell-Internalization SELEX of RNA Aptamers as a Starting Point for Prostate Cancer Research

2020 ◽  
pp. 245-254
Author(s):  
Mauricio Rodríguez-Dorantes ◽  
Sergio Alberto Cortés-Ramírez ◽  
Jenie Marian Cruz-Burgos ◽  
Juan Pablo Reyes-Grajeda ◽  
Alberto Losada-García ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Cancer Research ◽  
Rna Aptamers ◽  
Cell Internalization ◽  
Starting Point ◽  
Prostate Cancer Research

Inflammatory bowel disease and risk of prostate cancer: A matched-cohort analysis.

2019 ◽  
Vol 37 (7_suppl) ◽  
pp. 55-55
Author(s):  
Adam Weiner ◽  
Jacob A Burns ◽  
William J Catalona ◽  
Eric Li ◽  
Edward M. Schaeffer ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Inflammatory Bowel Disease ◽  
Bowel Disease ◽  
Cohort Analysis ◽  
Specific Antigen ◽  
Gleason Grade ◽  
Starting Point ◽  
Inflammatory Bowel ◽  
Clinically Significant

55 Background: There are few data on the risk of prostate cancer (PCa) in men with inflammatory bowel disease (IBD) and there are no data comparing serum prostate-specific antigen (PSA) values between men with IBD and matched men without IBD. Methods: This study retrospectively matched men with IBD based on race and age 1 to 9 to men without IBD (controls) who underwent PCa screening with at least one PSA at a single academic medical center from 1996 to 2017. Kaplan-Meier and multivariable Cox analyses were used to compare the risk of any and clinically significant PCa (Gleason grade group > 1) between the two groups adjusting for number of PSA tests, abnormal rectal exam, age, and race. A mix-effects regression was used to assess the association between PSA and IBD status. Results: After a median follow-up of 6.5 years for 1,033 men with IBD and 4.7 years for 9,306 controls, the median number of PSA tests was 2, 74% were white, and median age at first PSA (starting point of follow-up) was 53 years. At 10 years of follow-up, the incidence of any PCa was 0.65% for controls and 4.4% for men with IBD (HR 4.37, 95% CI 3.08-6.19, p < 0.001) and of clinically significant PCa was 0.42% for controls and 2.4% for men with IBD (HR 3.78, 95% CI 2.40-5.96, p < 0.001). When only men with IBD were assessed, use of biologic medications, duration of IBD diagnosis, history of bowel resection, Crohn’s disease versus ulcerative colitis were not associated with PCa diagnoses (all p > 0.1). Any steroid treatment for IBD was associated with decreased incidence of any PCa (HR 0.22, 95% CI 0.06-0.78, p = 0.019), but not with clinically significant PCa (p = 0.5). PSA values were higher among men with IBD starting at age 60 (1.12 ng/mL vs 1.04 ng/mL, p = 0.031) and this gap widened with increasing age (age 70: 1.54 ng/mL vs 1.32 ng/mL, p = 0.007). Conclusions: Men with IBD being screened for PCa had an increased incidence of all and clinically significant PCa compared to age- and race-matched controls and had increased PSA values at older age. These findings should be further validated to consider IBD as a risk factor for PCa and optimize screening for this population.

Alternative inflammatory cytokines pathways in prostate cancer: In search of new therapeutic options.

2020 ◽  
Vol 38 (15_suppl) ◽  
pp. e17504-e17504
Author(s):  
Marlena Janiczek ◽  
Łukasz Szylberg ◽  
Paulina Antosik ◽  
Andrzej Marszalek
Keyword(s):  
Prostate Cancer ◽  
Immune Response ◽  
Statistical Analysis ◽  
Gleason Score ◽  
Inflammatory Process ◽  
Inflammatory Factors ◽  
Control Group ◽  
Inflammatory Pathway ◽  
Gleason Grading ◽  
Starting Point

e17504 Background: The inflammatory reaction pathways have impact on tumor cells development or anti-tumor responses. Both by the activity of the innate and acquired immune response signalling pathways. A proper acquired immune response is considered as anti-tumor. While inadequate innate or acquired stimulation of the immune system can cause chronic inflammation that can lead to oncogenesis. Numerous reports have revealed a relationship between chronic prostatitis and prostate cancer (PCa). The aim of the study is to retrospectively assess the histological material of PCa with the Gleason grading score. The histological material evaluated the level of inflammatory factors of pathways initiated by IL-17A and IL-17F. The evaluation of the expression of pro-inflammatory factors such as IL-17A, IL-17F, IL-17RA, IL-17RC, AKT1, EBPbeta, TRAF 6 and NF-kB made it possible to assess the influence of the inflammatory process on the progression of PCa. Methods: Studies were carried out on archival tissue material in the form of paraffin blocks of 40 men with PCa after radical prostatectomy. The control group of 10 men with benign prostatic hyperplasia (BPH). The material was obtained by the transurethral resection of the prostate (TURP). The immunohistochemistry was performed on the material prepared in this way using specific primary antibodies against IL-17A, IL-17F, IL-17RA, IL-17RC, ACT1, TRAF-6, C/EBPbeta and NF-kB. The expression of the antibody to be examined using the light microscopy and the Remmele Stegner score (IRS) in cancer staining were then evaluated. Statistical analysis was performed using the non-parametric Kruskal-Wallis test. Results: In statistical analysis, it was shown that the inflammatory pathway IL17A/IL-17RC/TRAF6/NF-kB occurs in both BPH and PCa. IL-17 RA did not show expression in any group of patients and in the control group. In addition, along with the increase in the grading of Gleason score, a decrease in the expression of the tested inflammatory parameters was demonstrated. Conclusions: The inflammatory process has an impact on the cancer of prostate cancer. There is a correlation between the grades according to Gleason score and the level of expression of inflammation parameters. Activation of the inflammatory pathway through IL17A/IL-17RC/TRAF6/NF-kB cascade could correlate PCa development on the base of BPH. Evaluation of the inflammatory pathway in PCa, the initiated IL-17, may become a starting point for further research on an attempt to use, for example, immunotherapy in PCa.

scholarly journals Comparison of Physician-Documented Versus Patient-Reported Collection of Comorbidities Among Patients With Prostate Cancer Upon First Visit to the Urology Clinic

2018 ◽  
pp. 1-10 ◽  
Author(s):  
Katherine Fleshner ◽  
Amy Tin ◽  
Nicole Benfante ◽  
Sigrid Carlsson ◽  
Andrew J. Vickers
Keyword(s):  
Prostate Cancer ◽  
Medical History ◽  
Online Survey ◽  
Statistical Significance ◽  
Complete Information ◽  
Frequency Distributions ◽  
Physician Review ◽  
Starting Point ◽  
Patient Reported ◽  
Urology Clinic

Purpose To determine whether patient-reported collection of comorbidities online is sufficiently accurate to warrant use as part of a physician-reviewed, baseline medical history. Methods Comorbidities were collected for a sample of 213 new prostate cancer visits to our urology clinic through an online survey (called Baseline Medical History) before the clinical encounter. The frequency distributions of comorbidities as reported by patients before physician review were compared with those documented by physicians for a sample of 298 consecutive patients presenting to the same urology clinic before the survey went live. Results The overall frequency distribution of comorbidities and life expectancy estimates were similar between the two groups. A few comorbidity categories were reported with higher frequency in the patient-reported group compared with the physician-documented group, including neurologic comorbidities (7.5% v 1.7%; difference 6%; 95% CI, 2.0% to 10%; P = .001) and back pain (24% v 13%; difference 12%; 95% CI, 4.8% to 19%; P = .001). A similar trend was seen for vascular conditions, although the difference did not meet conventional levels of statistical significance. Genitourinary comorbidities, including problems with urination and erectile dysfunction, were better captured by the physician-reported group compared with the patient-reported group (68% v 53%; difference 15%; 95% CI, 7% to 24%; P = .001), as were other musculoskeletal comorbidities (8.7% v 1.9%; difference 7%; 95% CI, 3.2% to 11%; P = .001). Conclusion Patients completing a medical history, at their own pace and in the comfort of their own home, provide relatively accurate and complete information, even before physician review. Patient reporting of comorbidities thus seems to be a reliable starting point for the documentation of the medical history in the clinic.

The impact of time of medical oncologist visit on survival among elderly patients with stage IV prostate cancer: An analysis using SEER-Medicare data

2009 ◽  
Vol 27 (15_suppl) ◽  
pp. e17509-e17509
Author(s):  
C. D. Mullins ◽  
E. Onukwugha ◽  
B. Seal ◽  
A. Hussain ◽  
A. Hussain
Keyword(s):  
Prostate Cancer ◽  
Stage Iv ◽  
Survival Models ◽  
Medical Oncologist ◽  
Sample Mean ◽  
Medicare Data ◽  
Risk Of Mortality ◽  
Starting Point ◽  
Medicare Database ◽  
The Impact

e17509 Background: The association between physician referrals and treatment receipt has been established in other disease settings. The impact of time to a medical oncologist or hematologist/oncologist (MOH) visit on survival has not been examined in patients (pts) with advanced prostate cancer (A-PC). The objective of this study is to determine whether the time to a MOH visit is associated with survival. Methods: The SEER-Medicare database was used for the analysis. Pts aged >65 diagnosed with A-PC between 1994 and 2002 and who visited a urologist post-diagnosis were included. Pts who saw a MOH before the urologist visit were excluded. For pts who saw a MOH, time to a MOH visit was identified using the diagnosis date and the urologist visit as starting points. Survival models were used to examine the effect of the time (in months) to MOH visit on survival, controlling for demographic, clinical, continuity-of-care, and ecological measures. Results: There were 6,498 pts in the sample (mean age 76 years, 82% White race). PC-specific mortality was 38%. Two-thirds (67%) of patients did not visit a MOH after visiting a urologist. Among those with a visit to a MOH, an additional month from diagnosis till the MOH visit was positively associated with PC mortality (HR: 1.03; p < 0.001) - i.e. a shorter time to a MOH visit was associated with PC survival. Similar results were obtained using the month of the urologist visit as the starting point (HR: 1.02; p < 0.001). Conclusions: Among A-PC patients who are referred to an oncologist, each additional month between diagnosis/urologist visit and the oncologist visit is associated with an increased relative risk of mortality. [Table: see text]

Sign in / Sign up

Export Citation Format

Share Document